NewAmsterdam Pharma (NAMS) Other Non-Current Assets (2022 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Other Non-Current Assets data on file, last reported at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets changed N/A year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (changed N/A YoY), and the FY2023 full-year result was $35000.0, down 77.56% from the prior year.
• Other Non-Current Assets grew to $2.6 million in Q1 2026, from $8000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $2.6 million in Q1 2026 to a low of $101.27 in Q2 2023.
• A 4-year average of $440708.4 and a median of $12000.0 in 2024 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets surged 23396.85% in 2023 and soared 7799.68% in 2024, its largest moves.
• Tracing NAMS's Other Non-Current Assets over 4 years: stood at $148.96 in 2022, then surged by 23396.85% to $35000.0 in 2023, then slumped by 77.14% to $8000.0 in 2024, then jumped by 32212.5% to $2.6 million in 2026.
• Business Quant data shows NAMS's Other Non-Current Assets at $2.6 million in Q1 2026, $8000.0 in Q2 2024, and $16000.0 in Q1 2024.